metformin has been researched along with Ischemic Stroke in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Ischemic Stroke: Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT." | 9.41 | Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021) |
| "Preclinical studies have shown that metformin has neuroprotective actions in stroke." | 8.31 | Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study. ( Dang, M; Feng, Y; Jian, Y; Li, T; Li, Y; Lu, J; Lu, Z; Wang, H; Wang, X; Yang, Y; Zhang, G; Zhang, L; Zhang, Y; Zhao, L, 2023) |
| "To study the effects of metformin use and vitamin B12 deficiency on stroke rate among patients with T2DM." | 8.31 | The Effect of Metformin on Vitamin B12 Deficiency and Stroke. ( Abu Dahoud, W; Blum, A; Hajouj, T; Horrany, N; Moallem, Y; Zreik, M, 2023) |
| "To explore the association between the use of metformin and the risk of ischemic stroke in patients with type 2 diabetes." | 8.31 | [Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cohort study]. ( Chen, DF; Hu, YH; Qin, XY; Wang, MY; Wang, SY; Wu, JH; Wu, T; Wu, YQ; Yang, RT; Yu, H, 2023) |
| "In this study, we showed that pre-stroke metformin use was associated with favorable outcome after acute ischemic stroke in patients with diabetes mellitus type 2." | 8.12 | Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus. ( den Hertog, HM; Haalboom, M; Heijmans, E; Kersten, CJBA; Knottnerus, ILH; Zandbergen, AAM, 2022) |
| "We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT." | 5.41 | Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021) |
| "Preclinical studies have shown that metformin has neuroprotective actions in stroke." | 4.31 | Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study. ( Dang, M; Feng, Y; Jian, Y; Li, T; Li, Y; Lu, J; Lu, Z; Wang, H; Wang, X; Yang, Y; Zhang, G; Zhang, L; Zhang, Y; Zhao, L, 2023) |
| "In this population-based study, SGLT2is were associated with significant CV, renal and survival benefits among individuals with type 2 diabetes on metformin; the CV benefit was driven by a reduced risk of ischemic stroke." | 4.31 | Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. ( Garcia Rodriguez, LA; Gonzalez Perez, A; Lind, M; Sáez, ME; Vizcaya, D, 2023) |
| "To study the effects of metformin use and vitamin B12 deficiency on stroke rate among patients with T2DM." | 4.31 | The Effect of Metformin on Vitamin B12 Deficiency and Stroke. ( Abu Dahoud, W; Blum, A; Hajouj, T; Horrany, N; Moallem, Y; Zreik, M, 2023) |
| "To explore the association between the use of metformin and the risk of ischemic stroke in patients with type 2 diabetes." | 4.31 | [Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cohort study]. ( Chen, DF; Hu, YH; Qin, XY; Wang, MY; Wang, SY; Wu, JH; Wu, T; Wu, YQ; Yang, RT; Yu, H, 2023) |
| "In this study, we showed that pre-stroke metformin use was associated with favorable outcome after acute ischemic stroke in patients with diabetes mellitus type 2." | 4.12 | Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus. ( den Hertog, HM; Haalboom, M; Heijmans, E; Kersten, CJBA; Knottnerus, ILH; Zandbergen, AAM, 2022) |
| "To compare the risk of myocardial infarction (MI), ischemic stroke, or cardiovascular death in patients with T2D treated with mitoKATP channel high-affinity sulfonylureas and low-affinity sulfonylureas as add-on to metformin." | 4.12 | Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin. ( Hsu, YJ; Huang, YL; Lai, JH; Lee, CH; Lin, C; Lin, TC; Pan, HY; Wang, MT; Wang, PC; Wu, LW, 2022) |
| "In patients with T2DM, SGLT2i as first-line treatment may be associated with decreased events of heart failure hospitalization, acute coronary syndrome, and all-cause mortality, compared with metformin as first-line treatment." | 3.96 | Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study. ( Chang, CH; Chen, DY; Chen, SW; Chen, TH; Chu, PH; Li, YR; Lin, YS; Mao, CT; Sun, CC; Wu, M; Wu, VC, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osei, E | 1 |
| Zandbergen, A | 1 |
| Brouwers, PJAM | 1 |
| Mulder, LJMM | 1 |
| Koudstaal, P | 1 |
| Lingsma, H | 1 |
| Dippel, DWJ | 1 |
| den Hertog, H | 1 |
| Kersten, CJBA | 1 |
| Knottnerus, ILH | 1 |
| Heijmans, E | 1 |
| Haalboom, M | 1 |
| Zandbergen, AAM | 1 |
| den Hertog, HM | 1 |
| Jian, Y | 3 |
| Wang, H | 3 |
| Zhao, L | 3 |
| Li, T | 3 |
| Zhang, L | 4 |
| Wang, X | 3 |
| Zhang, Y | 3 |
| Li, Y | 3 |
| Dang, M | 3 |
| Lu, Z | 3 |
| Lu, J | 3 |
| Feng, Y | 3 |
| Yang, Y | 4 |
| Zhang, G | 3 |
| Wang, MT | 2 |
| Pan, HY | 2 |
| Huang, YL | 2 |
| Wu, LW | 2 |
| Wang, PC | 2 |
| Hsu, YJ | 2 |
| Lin, TC | 2 |
| Lin, C | 2 |
| Lai, JH | 2 |
| Lee, CH | 2 |
| Gonzalez Perez, A | 1 |
| Vizcaya, D | 1 |
| Sáez, ME | 1 |
| Lind, M | 1 |
| Garcia Rodriguez, LA | 1 |
| Zhang, J | 1 |
| Zhu, X | 1 |
| Jiao, W | 1 |
| Wu, Y | 1 |
| Yang, L | 1 |
| Wang, Y | 1 |
| Horrany, N | 1 |
| Abu Dahoud, W | 1 |
| Moallem, Y | 1 |
| Hajouj, T | 1 |
| Zreik, M | 1 |
| Blum, A | 1 |
| Yu, H | 1 |
| Yang, RT | 1 |
| Wang, SY | 1 |
| Wu, JH | 1 |
| Wang, MY | 1 |
| Qin, XY | 1 |
| Wu, T | 1 |
| Chen, DF | 1 |
| Wu, YQ | 1 |
| Hu, YH | 1 |
| Chen, TH | 1 |
| Li, YR | 1 |
| Chen, SW | 1 |
| Lin, YS | 1 |
| Sun, CC | 1 |
| Chen, DY | 1 |
| Mao, CT | 1 |
| Wu, M | 1 |
| Chang, CH | 1 |
| Chu, PH | 1 |
| Wu, VC | 1 |
1 trial available for metformin and Ischemic Stroke
| Article | Year |
|---|---|
Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
Topics: Blood Glucose; Brain Ischemia; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2021 |
8 other studies available for metformin and Ischemic Stroke
| Article | Year |
|---|---|
Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus.
Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Stroke; Treatment Out | 2022 |
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies | 2023 |
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies | 2023 |
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies | 2023 |
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies | 2023 |
Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
Topics: Adenosine Triphosphate; Cohort Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycem | 2022 |
Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
Topics: Adenosine Triphosphate; Cohort Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycem | 2022 |
Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
Topics: Adenosine Triphosphate; Cohort Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycem | 2022 |
Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
Topics: Adenosine Triphosphate; Cohort Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycem | 2022 |
Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Middle Aged; Myocardi | 2023 |
Metformin enhances neural precursor cells migration and functional recovery after ischemic stroke in mice.
Topics: Animals; Bromodeoxyuridine; Cell Differentiation; Infarction, Middle Cerebral Artery; Ischemic Strok | 2023 |
The Effect of Metformin on Vitamin B12 Deficiency and Stroke.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ischemic Stroke; Metformin; Prospective Stud | 2023 |
[Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cohort study].
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ischemic Strok | 2023 |
Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Topics: Acute Coronary Syndrome; Adult; Aged; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus | 2020 |